Advaxis Investor and Analyst Day 2016

Advaxis presented updates on its lead immunotherapy candidate axalimogene filolisbac (AXAL) for HPV-associated cancers at its second NYC investor and analyst day. The presentation highlights clinical trial developments and the company's progress in leveraging Listeria monocytogenes-based immunotherapy to educate the immune system to recognize and attack cancer cells.